intern
confer
antivir
research
icar
held
la
jolla
ca
usa
april
report
open
tribut
late
chri
mcguigan
pastpresid
isar
continu
summari
princip
invit
lectur
doug
richman
elion
award
investig
hiv
resist
bob
vinc
award
show
carbocycl
nucleosid
analog
led
abacavir
jerom
deval
prusoff
award
explain
group
chose
seek
nucleosid
analog
treat
rsv
activ
human
rsvchalleng
studi
evalu
children
first
keynot
address
richard
h
scheuermann
report
remark
progress
made
viral
genom
second
keynot
address
heinz
feldmann
gave
overview
ebola
viru
diseas
four
minisymposia
structur
biolog
diagnost
technolog
dna
virus
zika
viru
diagnost
assay
approach
ideal
aim
compact
instrument
simpl
use
type
sampl
sampl
prepar
result
within
hour
divers
hcmv
far
greater
herpesvirus
typic
individu
singl
nucleotid
polymorph
snp
antivir
treatment
rapid
cmv
evolut
presum
due
preferenti
select
alreadi
present
variant
rather
creation
new
variant
select
contributor
present
includ
oral
prodrug
nucleosid
triphosph
analog
new
method
synthesi
phosphoramid
prodrug
clinic
evalu
brincidofovir
treat
transplant
recipi
adenoviru
infect
articl
provid
overview
invit
lectur
intern
confer
antivir
research
icar
sponsor
intern
societi
antivir
research
isar
held
la
jolla
ca
usa
april
year
meet
open
heartfelt
tribut
andrea
brancal
mentor
colleagu
chri
mcguigan
die
march
meet
summari
continu
report
lectur
recipi
isar
three
major
award
held
memori
gertrud
trudi
elion
toni
william
bill
prusoff
follow
summari
two
keynot
address
main
present
within
four
minisymposia
structur
biolog
diagnost
technolog
dna
virus
zika
viru
four
contributor
present
review
articl
simpli
provid
short
account
oral
present
gener
accompani
refer
scientif
literatur
descript
favor
treatment
outcom
taken
recommend
clinic
use
gener
ad
person
comment
meet
within
conclus
instanc
ad
comment
within
main
text
indic
either
word
use
squar
bracket
although
meet
report
cover
present
aim
illustr
great
divers
topic
discuss
icar
bring
togeth
knowledg
expertis
wide
spectrum
antivir
research
chri
obtain
bsc
chemistri
hon
class
univers
birmingham
phd
anticanc
drug
design
move
univers
edmonton
alberta
canada
postdoctor
fellow
univers
exet
demonstr
univers
colleg
london
lectur
univers
southampton
lectur
career
welsh
school
pharmaci
began
reader
professor
becom
pro
vice
chancellor
professor
chri
inspir
leader
train
phd
postdoc
present
work
variou
icar
chri
publish
paper
obtain
patent
isar
select
chri
first
person
receiv
william
prusoff
young
investig
award
year
later
chri
elect
isar
presidentelect
becom
presid
two
year
later
collabor
erik
de
clercq
jan
balzarini
led
discoveri
fig
highli
potent
activ
varicella
viru
vzv
current
phase
iii
clinic
trial
patient
herp
zoster
shingl
clearli
chri
delight
present
jan
elion
award
fig
anoth
compound
often
synthesis
quickli
ship
inhibitex
nov
shown
excel
activ
hepat
c
viru
hcv
ec
nm
clinic
mileston
quickli
achiev
first
man
may
first
efficaci
patient
mar
unfortun
trial
stop
due
toxic
concern
howev
prove
phosphoramid
prodrug
approach
success
adopt
other
perhap
evid
legaci
chri
work
repres
sofosbuvir
fig
tenofovir
alafenamid
backbon
compound
gilead
singletablet
regimen
str
treat
patient
infect
hcv
hiv
respect
move
phosphoramid
protid
approach
sideway
antivir
anticanc
acelarin
fig
licens
nucana
phase
iii
studi
termin
ill
patient
grow
tumour
good
diseas
control
particularli
advanc
gynaecolog
cancer
envisag
acelarin
use
chemotherapi
reduc
develop
resist
often
limit
efficaci
standard
chemotherapi
andrea
end
tribut
highli
person
note
chri
mentor
colleagu
friend
die
soon
thought
go
famili
lost
husband
father
may
add
comment
andrea
mention
chri
first
recipi
prusoff
award
mind
award
lectur
set
new
standard
day
masteri
slide
creation
visual
excit
clear
inform
rare
equal
report
icar
mention
prusoff
award
lectur
erica
ollmann
saphir
sail
straight
top
ten
icar
lectur
top
ten
certainli
includ
prusoff
award
lectur
chri
present
style
uniqu
memor
even
year
last
memori
chri
excitedli
show
us
photo
newborn
daughter
mayb
import
legaci
mani
young
scientist
help
includ
andrea
brancal
gave
heartfelt
tribut
mentor
colleagu
friend
andrea
activ
member
icar
mani
year
isar
webmast
sinc
gertrud
elion
memori
award
lectur
antiretrovir
drug
histori
futur
dougla
doug
richman
univers
california
san
diego
la
jolla
ca
usa
doug
fig
first
paid
tribut
trudi
elion
pioneer
work
nucleosid
elion
award
lectur
doug
briefli
describ
difficulti
earli
day
hiv
epidem
end
bright
prospect
treatment
prevent
aid
first
describ
hiv
human
immunedefici
viru
discov
azt
deoxythymidin
first
drug
show
antiretrovir
activ
first
clinic
data
report
lancet
yarchoan
et
al
juli
efficaci
azt
treatment
patient
aid
aidsrel
complex
report
new
england
journal
medicin
nejm
time
largescal
longterm
trial
subject
week
week
death
azt
group
vs
placebo
group
one
studi
suffici
fda
approv
even
first
trial
clear
warn
sign
group
less
serious
ill
patient
aidsrel
complex
cell
count
azt
group
remain
significantli
p
higher
placebo
group
week
week
patient
give
clear
result
aid
group
treat
azt
mean
cell
count
remain
higher
placebo
group
week
howev
initi
rise
baselin
week
steadi
declin
sequenti
hiv
isol
design
taken
month
individu
patient
treat
azt
log
reduct
azt
suscept
larder
et
al
doug
comment
grant
applic
investig
hiv
resist
turn
review
assert
essenti
enzym
viru
replic
could
toler
mutat
doug
recal
comment
arthur
schopenhau
note
truth
pass
three
stage
first
ridicul
second
violent
oppos
third
accept
selfevid
next
decad
becam
clear
hiv
resist
problem
class
antiretrovir
monotherapi
sequenti
monotherapi
led
multiclass
resist
resist
hiv
transmit
combin
therapi
indinavir
idv
azt
lamivudin
vs
idv
alon
gave
best
efficaci
reduct
hiv
rna
throughout
twoyear
studi
merck
nejm
studi
show
way
forward
sever
combin
abl
reduc
plasma
hiv
rna
level
limit
detect
copiesml
time
year
present
new
drug
new
drug
combin
receiv
fda
approv
notabl
advanc
approv
truvada
tdf
prodrug
tenofovir
introduct
atripla
first
singletablet
regimen
str
approv
tenofovir
alafenamid
taf
combin
analysi
two
phase
iii
studi
compar
stribild
contain
tdf
combin
taf
primari
efficaci
outcom
slightli
favour
taf
arm
tdf
arm
week
patient
undetect
hiv
rna
copiesml
respect
week
respect
one
import
point
week
current
regimen
virolog
failur
resist
respect
resist
strain
genotyp
suscept
dolutegravir
although
efficaci
paramet
taf
tdf
similar
taf
arm
improv
safeti
profil
approv
improv
therapi
better
understand
use
proport
patient
newli
detect
drug
resist
decreas
year
antiretrovir
art
initi
mark
improv
compar
therapi
initi
prior
easier
avoid
drug
resist
limit
follow
suboptim
therapi
unfortun
transmit
drug
resist
still
problem
especi
patient
art
year
steadi
increas
estim
proport
hivinfect
patient
receiv
art
increas
larg
due
patient
africa
receiv
art
million
patient
worldwid
art
million
africa
posit
side
estim
million
death
avert
neg
side
wide
anticip
factor
contribut
hiv
drug
resist
low
middl
incom
countri
lmic
confirm
suboptim
regimen
limit
resourc
monitor
viral
load
drug
distribut
failur
perinat
art
rather
treat
pregnant
women
futur
hold
short
term
avail
taf
dolutegravir
dtg
provid
mark
improv
art
lmic
look
ahead
prospect
art
prolong
interv
sever
month
dose
cabotegravir
cab
fig
integras
inhibitor
investig
phase
trial
n
subjectscohort
compar
monthli
quarterli
repeat
dose
cohort
load
dose
ld
mg
intramuscular
im
follow
mainten
dose
md
cab
either
mg
subcutan
sc
q
w
time
mg
im
q
w
time
mg
im
q
w
time
mg
im
w
respect
target
plasma
concentr
cab
mgml
w
dose
interv
cab
trough
level
mg
ml
mg
sc
im
dose
similar
less
mg
im
dose
trough
level
mgml
respect
cab
rilpivirin
rpv
hiv
nnrti
develop
longact
inject
nanosuspens
phase
iib
trial
cab
rpv
im
compar
oral
art
cab
patient
randomis
induct
period
treat
daili
oral
cab
mg
patient
achiev
rna
cml
elig
start
mainten
period
mp
enrol
patient
randomis
cab
rpv
everi
week
q
w
everi
week
q
w
remain
oral
cab
n
respect
primari
endpoint
safeti
virolog
failur
hiv
rna
cml
week
mp
intent
treatmainten
expos
ittm
excel
virolog
success
patient
respect
maintain
undetect
hiv
rna
level
nonrespond
hiv
rna
cml
respect
patient
discontinu
due
lack
efficaci
one
q
w
oral
group
seem
good
safeti
profil
inject
site
reaction
common
accept
deoxyadenosin
efda
fig
develop
merck
licens
yamasa
efda
highli
potent
hiv
rt
inhibitor
pbmc
ec
nm
nonoblig
chain
termin
prevent
transloc
rt
follow
singl
oral
dose
mgkg
rhesu
macaqu
peak
plasma
concentr
efda
mm
reduc
nm
nearli
h
day
rhesu
pbmc
efda
taken
convert
diphosph
dp
triphosph
tp
rapidli
mm
first
time
point
day
dp
tp
mm
suggest
potenti
onceaweek
oral
dose
phase
ib
studi
singl
mg
oral
dose
hivinfect
patient
result
log
decreas
viral
load
day
intracellular
halflif
efdatp
h
evid
resist
day
log
decreas
viral
load
parenter
formul
given
effect
drug
level
day
suggest
twiceyearli
dose
possibl
cab
efda
look
set
transform
hiv
therapi
like
induct
period
use
oral
dose
necessari
due
safeti
concern
event
hypersensit
reaction
thereaft
inject
time
year
could
give
effect
art
patient
hiv
infect
prevent
transmiss
uninfect
subject
problem
associ
poor
deliveri
art
henc
potenti
hiv
resist
pmic
may
larg
avoid
prospect
interrupt
hiv
transmiss
hold
hope
hiv
epidem
may
gradual
control
robert
bob
vinc
center
drug
design
univers
minnesota
mn
usa
bob
fig
start
acknowledg
public
toni
influenc
work
join
laboratori
led
howard
schaeffer
team
focuss
nucleic
acid
chemistri
bob
inspir
molecular
biolog
cours
nucleic
acid
first
year
graduat
school
taught
professor
roger
mantsavino
arriv
erwin
chargaff
lab
columbia
univers
howard
move
burrough
wellcom
becom
head
medicin
chemistri
divis
bob
move
univers
minnesota
bob
thank
bill
shannon
attend
mani
icar
includ
one
longterm
collabor
bob
propos
design
synthesi
acyclonucleosid
potenti
antitumor
antivir
agent
base
lectur
present
dr
mantsavino
first
seri
acycloadenosin
publish
j
med
chem
although
howard
schaeffer
synthesis
compound
draft
paper
move
burrough
wellcom
sent
letter
bob
suggest
bob
author
idea
synthes
acyclonucleosid
compound
shown
substrat
adenosin
deaminas
e
biolog
activ
molecul
remain
unknown
could
recognis
kinas
form
correspond
monophosph
acycloadenosinemp
howard
move
burrough
wellcom
bob
move
minnesota
idea
shelv
acycloguanosin
later
found
activ
antiherp
agent
burrough
wellcom
subsequ
schaffer
et
al
antiherpesviru
activ
acycloguanosin
publish
decad
later
acyclovir
acv
oral
prodrug
valacyclovir
vacv
still
use
interest
note
tenofovir
synthesis
toni
also
acyclonucleotid
e
includ
prodrug
use
singletablet
regimen
str
therapi
hiv
infect
patient
araadenosin
araa
known
antiherpesviru
compound
activ
kinas
give
mono
diand
triphosph
inhibit
viral
polymeras
howev
araa
also
substrat
adenosin
deaminas
give
arainosin
inact
bob
wonder
correspond
carbocycl
araa
would
stabl
compound
known
cyclaradin
adenosin
deaminaseresist
low
system
toxic
bob
due
present
synthesi
cyclaradin
meet
told
bill
shannon
southern
research
institut
found
compound
good
activ
herp
simplex
viru
type
suggest
bob
consid
withdraw
present
unawar
patent
implic
bob
deliv
present
plan
import
lesson
learnt
hard
way
methoxyacet
prodrug
cyclaradinema
fig
activ
topic
model
genit
infect
guinea
pig
cyclaradinema
topic
formul
compar
acv
compound
good
activ
model
cyclaradin
appar
slightli
greater
activ
fig
unexpectedli
mark
differ
followup
period
acv
treatment
recurr
wherea
recurr
follow
cyclaradinema
treatment
bob
bill
shannon
coauthor
public
vinc
et
al
although
cyclaradin
seem
interest
compound
develop
could
compound
patent
protect
next
major
advanc
came
synthesi
guanosin
analog
becam
known
carbovir
fig
cyclaradin
oxygen
replac
carbon
doubl
bond
use
give
ring
similar
shape
ribofuranos
mei
hua
synthesis
first
carbovir
compound
improv
oral
bioavail
variou
alkyl
analog
carbovir
synthesis
fig
compound
activ
hiv
rt
inhibitor
analog
convert
intracellularli
carbovirmp
phosphoryl
activ
carbovirtp
decemb
patent
file
bob
mei
inventor
carbovir
licens
glaxosmithklin
gsk
cyclopropylcarbovir
synthesis
gsk
claim
cycloalkyl
chain
cover
patent
howev
alkyl
analog
carbovir
cyclopropyl
carbovir
convert
carbovirmp
activ
form
carbovirtp
follow
lawsuit
gsk
pay
univers
minnesota
million
royalti
although
cyclopropyl
group
essenti
gsk
done
much
work
compound
carbovir
analog
develop
becom
abacavir
royalti
enabl
univers
start
fund
center
drug
design
bob
director
jerom
note
smallmolecul
drug
approv
neg
strand
rna
virus
none
viru
replic
inhibitor
singl
rna
viru
replic
inhibitor
clinic
trial
known
favipiravir
approv
japan
treat
seriou
influenza
infect
phase
iii
trial
usa
favipiravir
phase
iii
phase
ii
trial
respect
influenza
infect
five
compound
phase
trial
bcx
ebola
viru
infect
includ
icar
lectur
respect
one
compound
test
respiratori
syncyti
viru
rsv
infect
subject
present
compound
viral
polymeras
inhibitor
four
favipiravir
nucleosid
analog
effect
therapeut
rsv
infect
may
seriou
even
fatal
children
clearli
import
unmet
clinic
need
although
main
rsv
target
potenti
drug
fusion
protein
part
polymeras
complex
jerom
colleagu
decid
screen
nucleosid
analog
past
experi
herp
virus
vzv
hiv
hbv
hcv
shown
nucleosid
analog
provid
drug
good
broadspectrum
activ
mani
strain
viru
shown
high
genet
barrier
limit
problem
due
viru
resist
therefor
small
screen
campaign
initi
select
structur
divers
nucleosid
analog
test
activ
rsv
vs
lack
inhibit
cellular
replic
screen
result
one
hit
azidocytidin
known
inhibit
hcv
also
known
safeti
issu
structureact
relationship
sar
studi
prove
difficult
aim
discov
compound
good
select
activ
rsv
measur
select
lack
activ
hcv
cellular
replic
mani
deadend
one
compound
emerg
good
candid
good
activ
rsv
ec
mm
test
b
clinic
isol
lack
cytotox
cc
mm
lack
activ
hcv
rhinoviru
rna
virus
influenza
viru
segment
rna
viru
howev
activ
rsv
also
two
nonseg
rna
virus
parainfluenza
viru
type
ec
mm
vesicular
stomat
viru
ec
mm
expect
nucleosid
antivir
activ
inhibit
rsv
rnadepend
rna
polymeras
rdrp
effici
phosphoryl
deoxycytidin
kinas
dck
human
primari
lung
cell
high
level
cell
form
halflif
h
inhibit
rsv
polymeras
ic
mm
parainfluenza
viru
type
ic
mm
polymeras
influenza
viru
hcv
collabor
rachel
fearn
boston
univers
confirm
incorpor
effici
rna
chain
rsv
polymeras
use
polyg
templat
less
natur
cytidinetp
residu
ad
chain
termin
first
exampl
rna
chain
termin
rsv
upon
prolong
incub
rsv
four
resist
mutat
design
quad
select
three
four
mutat
within
conserv
motif
b
polymeras
domain
l
protein
collabor
marti
moor
emori
univers
confirm
quad
mutat
introduc
l
gene
gave
resist
although
seem
promis
candid
compound
lack
suffici
oral
bioavail
variou
antivir
drug
possibl
prodrug
made
diisobutyl
ester
fig
select
primat
efficaci
model
oral
reduc
rsv
lung
sampl
log
limit
detect
log
nasal
sampl
phase
studi
n
oral
dose
regimen
three
dose
regimen
twice
daili
day
mg
dose
mg
ld
mg
md
dose
mg
ld
mg
md
dose
h
first
detect
rsv
morn
day
whichev
occur
first
subject
randomis
receiv
first
dose
placebo
primari
efficaci
end
point
area
curv
auc
viral
load
nasal
wash
determin
rtpcr
assay
rsv
rna
appear
advantag
load
dose
use
reduct
auc
viral
load
vs
placebo
respect
fig
secondari
end
point
clearanc
rate
rsv
rna
slope
viral
load
chang
rapid
two
regimen
load
dose
reduct
even
first
postdos
sampl
h
contrast
viral
load
placebo
group
peak
day
randomis
importantli
peak
rsv
viral
load
associ
peak
symptom
three
treat
group
mean
symptom
score
mucu
weight
remain
baselin
throughout
observ
period
proofofconcept
studi
suggest
efficaci
appear
activ
rsvfusion
inhibitor
test
previou
studi
similar
design
current
evalu
young
children
hope
result
may
avail
end
year
jerom
switch
focu
influenza
viru
favipiravir
approv
japan
seriou
influenza
infect
still
phase
iii
trial
usa
known
favipiravirtp
incorpor
influenza
rna
polymeras
either
basepair
cytidin
less
guanin
uridin
less
adenin
jerom
colleagu
interest
discov
polymeras
could
inhibit
favipiravirtp
confirm
noroviru
rna
polymeras
inhibit
also
favipiravirtp
substrat
human
mitochondri
rna
polymeras
find
suggest
opportun
discov
analog
favipiravir
better
specif
influenza
rna
polymeras
jerom
conclus
still
far
nucleosid
analog
howev
nonnucleosid
inhibitor
influenza
polymeras
earli
clinic
trial
exampl
although
suitabl
nucleosid
analog
may
hard
find
may
potenti
lead
effect
drug
open
resourc
inform
two
databas
set
influenza
wwwfludborg
viru
pathogen
resourc
wwwviprbrcorg
prior
complet
influenza
genom
sequenc
known
april
total
complet
genom
sequenc
known
influenza
nearli
sequenc
jcvi
larg
data
set
one
abl
seek
much
detail
antigen
drift
allow
season
influenza
thwart
preexist
immun
mani
immun
epitop
hemagglutinin
protein
ha
defin
experiment
bcell
epitop
form
continu
amino
acid
sequenc
other
discontinu
region
come
togeth
fold
ha
three
latter
design
sa
sb
possibl
bcell
epitop
import
protect
immun
work
hypothesi
site
within
epitop
b
cell
antibodi
ab
overlap
may
key
target
protect
immun
region
ha
protein
import
protect
immun
nonsynonym
substitut
select
base
chang
code
differ
amino
acid
compar
rate
nonsynonym
substitut
eg
cta
leu
caa
pro
dn
synonym
substitut
eg
cta
leu
ctg
leu
ds
possibl
find
amino
acid
posit
diversifi
expect
ie
ratio
dnd
larg
studi
season
clinic
sampl
taken
prior
pandem
diversifi
site
found
ha
locat
known
bcellab
epitop
includ
sa
sb
one
diversifi
bcellab
epitop
protein
would
diversifi
epitop
target
mutat
pandem
lineag
evolv
respons
develop
populationlevel
protect
immun
human
clinic
sampl
pandem
h
n
influenza
viru
collect
period
data
mine
approach
use
identifi
region
ha
protein
diversifi
therefor
may
target
protect
immun
human
earli
pandem
essenti
immun
infect
popul
season
commun
immun
becam
establish
late
pandem
season
viru
mutant
escap
exist
immun
would
favour
sequenc
three
situat
compar
prepandem
data
amino
acid
site
differ
significantli
prepandem
isol
isol
recent
influenza
season
three
site
locat
diversifi
bcellab
epitop
region
identifi
previous
includ
sa
sb
howev
addit
diversifi
site
known
bcellab
epitop
note
substitut
happen
seem
spread
worldwid
test
hypothesi
mutat
bcellab
region
import
protect
immun
monoval
vaccin
inactiv
use
rais
antisera
cohort
volunt
expect
hemagglutin
inhibit
assay
antisera
reduc
reactiv
recent
isol
summari
diversifi
epitop
appear
identifi
bcell
ab
epitop
key
protect
immun
human
although
possibl
predict
key
epitop
evolv
one
predict
particular
epitop
evolv
select
sequenc
variat
season
influenza
includ
chang
key
epitop
time
chang
new
vaccin
richard
switch
second
topic
e
enteroviru
outbreak
usa
within
period
midaugust
midjanuari
confirm
case
includ
death
infect
usual
mild
like
mani
unreport
case
also
within
period
unexpect
case
paralysi
unknown
etiolog
associ
infect
exampl
paralyz
children
co
usa
earlier
june
june
case
acut
flaccid
paralysi
afp
ca
usa
case
posit
afp
case
report
canada
franc
norway
australia
genet
chang
link
increas
diseas
sever
notabl
neurolog
symptom
answer
question
phylogenet
tree
creat
examin
use
number
statist
tool
discov
three
distinct
clade
cocircul
outbreak
paralysiscaus
isol
within
clade
variou
new
nucleotid
amino
acid
substitut
e
particular
interest
sequenc
also
found
equival
posit
paralysisassoci
polioviru
andor
isol
note
specif
clade
associ
neuropatholog
polioviru
infect
project
set
aim
make
target
substitut
variou
region
genom
utr
polymeras
gene
capsid
bind
gene
specif
mutat
virus
test
human
neuron
cell
use
polioviru
neurovirul
assay
nonneuron
cell
hela
comparison
hope
inform
emerg
link
sequenc
diseas
identif
diagnost
region
zika
viru
cover
briefli
problem
sever
flavivirus
cocircul
zika
virusendem
area
aim
find
viral
peptid
region
specif
viru
virus
dengu
viru
denv
type
ilheu
viru
ilhv
japanes
enceph
viru
jev
west
nile
viru
wnv
yellow
fever
viru
yfv
zika
viru
zikv
hope
develop
array
screen
serum
sampl
result
obtain
hour
rather
day
tradit
elisa
screen
ebola
viru
past
present
futur
heinz
feldmann
nation
institut
allergi
infecti
diseas
hamilton
mt
usa
heinz
fig
state
present
repres
thought
ebola
viru
first
recognis
new
viru
two
center
infect
one
near
ebola
river
zair
democrat
republ
congo
drc
sudan
near
border
drc
ebola
viru
close
relat
marburg
viru
filovirus
sporad
outbreak
ever
sinc
none
nearli
larg
recent
one
west
africa
worsthit
countri
guinea
liberia
sierra
leon
report
case
laboratori
confirm
death
ebola
viru
get
west
africa
one
suggest
via
bat
migrat
e
yet
isol
ebola
viru
bat
ebola
viru
lie
wait
long
time
strain
ebola
viru
design
makona
seem
differ
much
ebola
viru
previou
outbreak
central
africa
similar
virul
primat
compar
mutat
rate
similar
interferon
antagon
could
higher
transmiss
e
data
probabl
unlik
outbreak
seem
driven
variou
local
factor
poor
healthcar
system
mobil
popul
across
border
resist
due
lack
understand
viru
infect
tradit
custom
especi
burial
one
posit
outcom
outbreak
much
larger
cohort
survivor
previou
outbreak
much
data
collect
postebola
syndrom
musculoskelet
symptom
blur
vision
weight
loss
slowedmov
pain
frequent
headach
depress
chronic
pain
sexual
dysfunct
also
survivor
face
stigma
hinder
integr
back
commun
major
concern
find
ebola
viru
rna
found
survivor
mani
month
discharg
ebola
treatment
center
individu
case
studi
suspect
sexual
transmiss
confirm
ebola
rna
detect
transmiss
viru
remain
possibl
exampl
survivor
discharg
octob
month
later
march
patient
unprotect
sex
survivor
week
later
patient
symptom
ebola
infect
confirm
march
survivor
semen
posit
ebola
viru
rna
survivor
patient
distinct
ebola
viru
sequenc
recommend
male
survivor
either
abstain
use
condom
semen
test
regularli
neg
sinc
first
ebola
outbreak
difficult
differenti
malaria
ebola
viru
infect
height
ebola
outbreak
west
africa
mani
patient
ebola
viru
malaria
parasit
plasmodium
ebola
viru
plasmodium
onethird
neither
ebola
malaria
unknown
caus
one
surpris
find
presenc
plasmodium
seem
increas
surviv
rate
ebola
infect
throughout
ebola
outbreak
west
africa
approv
drug
treat
ebola
infect
favipiravir
viru
polymeras
inhibitor
approv
japan
seriou
influenza
infect
test
guinea
toward
end
outbreak
seem
benefit
patient
low
moder
base
line
viral
load
anoth
viral
polymeras
inhibitor
much
activ
favipiravir
ebola
nonhuman
primat
model
clinic
data
avail
howev
promis
drug
futur
ebola
outbreak
one
issu
delay
start
drug
vaccin
trial
ethic
concern
placebo
control
group
infect
high
risk
mortal
favipiravir
trial
agre
compar
group
would
histor
control
phase
vaccin
trial
two
hope
activ
vaccin
compar
induct
immun
respons
placebo
group
ring
vaccin
trial
vaccin
administ
either
immedi
short
delay
see
notabl
lack
publish
result
two
vaccin
express
ebola
viru
glycoprotein
gp
test
late
ebola
outbreak
chimpanze
adenoviru
type
develop
glaxosmithklin
recombin
vesicular
stomat
viru
vector
rvsvzebov
develop
newlinkmerck
two
rvsvzebov
test
ring
vaccin
cluster
trial
cluster
randomis
vaccin
either
immedi
short
delay
day
follow
index
case
identif
vaccin
seem
highli
effect
prevent
ebola
diseas
vaccin
seem
provid
protect
within
day
vaccin
shown
good
efficaci
within
week
primat
model
rvsvebov
pfu
administ
intramuscularli
im
either
day
prior
challeng
pfu
ebovmakona
im
n
control
group
administ
unrel
vsvvector
vaccin
day
group
develop
good
antibodi
level
time
challeng
day
group
give
detect
antibodi
level
prior
challeng
level
rose
quickli
next
day
surviv
essenti
symptom
group
reduc
surviv
day
group
survivor
control
group
ongo
effort
improv
outcom
futur
ebola
outbreak
strengthen
public
health
improv
commun
awar
negoti
crossbord
cooper
continu
intern
support
although
rvsvebov
vaccin
deem
safe
use
unwelcom
side
effect
e
safer
vaccin
desir
clinic
trial
potenti
drug
eg
clinic
efficaci
trial
must
start
immedi
preapprov
trial
protocol
major
advanc
instrument
smaller
easier
use
detect
sequenc
sampl
ebola
patient
eas
set
requir
infrastructur
futur
need
adequ
stockpil
drug
vaccin
far
worst
ebola
outbreak
tool
limit
futur
ebola
outbreak
minisymposium
organis
three
past
winner
prusoff
award
andrea
brancal
bruno
canard
erica
ollmann
saphir
success
structurebas
design
antiaid
drug
target
revers
transcriptas
overcom
resist
strateg
flexibl
eddi
arnold
rutger
univers
piscataway
nj
usa
hiv
rt
exist
sever
form
exampl
close
fist
chang
open
hand
grasp
nucleic
acid
nucleotid
substrat
structur
rt
bound
nonnucleosid
rt
inhibitor
nnrti
nucleic
acid
confirm
drug
prevent
incom
nucleotid
reach
activ
site
eddi
mention
longterm
collabor
late
paul
janssen
johnson
johnson
togeth
discov
develop
two
hiv
drug
etravirin
approv
rilpivirin
approv
explain
efficaci
drug
even
mutant
hiv
strain
flexibl
hypothesi
propos
flexibl
molecul
option
fit
pocket
even
mutat
recent
arnold
group
start
use
fragment
screen
aim
discov
new
drugbind
site
rna
viral
nucleas
genom
stabil
innat
immun
evas
ferron
centr
nation
de
la
recherch
scientifiqu
aixmarseil
univers
marseil
franc
singlestrand
ss
rna
ss
rna
virus
rare
encod
nucleas
strikingli
arenavirida
coronavirida
two
viral
famili
encod
two
viral
nucleas
endonucleas
exonucleas
role
nucleas
play
viru
replic
would
role
suffici
critic
make
nucleas
valid
antivir
target
arenavirida
ss
rna
virus
short
biseg
genom
encod
protein
involv
replicationtranscript
contrast
coronavirida
ss
rna
virus
long
genom
kb
code
protein
replic
although
arenavirida
protein
replic
larg
l
protein
multifunct
domain
associ
endonucleas
activ
polymeras
activ
capbind
properti
capsnatch
transfer
cap
attach
host
rna
viral
rna
effici
strategi
limit
viral
rna
degrad
cellular
exonucleas
three
viral
famili
arenavirida
bunyavirida
orthomyxovirida
endonucleas
part
polymeras
protein
use
capsnatch
therefor
inhibitor
endonucleas
enabl
host
exonucleas
degrad
viral
rna
prevent
viral
transcript
arenavirida
exonucleas
associ
domain
within
nucleoprotein
mutat
domain
restor
interferon
ifn
respons
viru
initi
screen
produc
potenti
activ
compound
one
compound
inhibit
endonucleas
activ
vitro
mm
lymphocyt
choriomening
viru
lcmv
crystal
structur
endonucleas
domain
complex
compound
obtain
virtual
screen
approach
exonucleas
led
identif
one
compound
activ
vitro
coronavirida
nonstructur
protein
nsp
involv
replic
nsp
exonucleas
nsp
endonucleas
interestingli
exonucleas
requir
bind
activ
vitro
sarscov
exonucleas
mutant
virus
defect
increas
mutat
frequenc
exonucleas
remov
one
mismatch
base
pair
model
sarscov
exonucleasedsrna
complex
given
insight
nucleosid
analog
excis
function
replic
complex
rdrp
reconstitut
three
compound
inhibitori
activ
vitro
summaris
expect
effect
inhibitor
arenavirida
endonucleas
reduc
transcript
exonucleas
restor
ifn
respons
likewis
inhibit
coronavirida
exonucleas
restor
ifn
respons
also
increas
mutat
rate
viral
replic
erica
ollmann
saphir
scripp
research
institut
san
diego
ca
usa
hemorrhag
fever
virus
includ
ebola
marburg
lassa
virus
surfac
virus
consist
glycoprotein
gp
highli
glycosyl
form
protect
coat
mucin
xray
light
scatter
reveal
structur
mucin
albeit
low
resolut
gp
produc
larg
quantiti
export
cell
domin
immun
respons
viral
hemorrhag
fever
immunotherapeut
consortium
vhfic
global
collabor
evalu
avail
monoclon
antibodi
mab
ebola
eventu
aim
repeat
later
virus
prusoff
award
lectur
icar
rome
vere
hodg
erica
describ
collabor
work
lead
zmapp
emerg
februari
august
zmapp
use
compassion
basi
treat
health
care
worker
repatri
usa
zmapp
consist
three
antibodi
bind
top
gp
recruit
immun
system
bind
base
gp
also
bind
base
gp
collabor
work
continu
investig
antibodi
obtain
survivor
recent
ebola
outbreak
aim
creat
cocktail
antibodi
panebola
efficaci
also
work
marburg
viru
ongo
far
major
antibodi
investig
bind
top
gp
minisymposium
organis
peiyong
shi
univers
texa
medic
branch
galveston
tx
heather
greenston
virolog
branch
niaidnih
rockvil
md
usa
peiyong
introduc
session
focus
potenti
treat
prevent
zika
viru
infect
one
start
learn
lesson
past
experi
dengu
virus
inhibitor
specif
design
dengu
taken
clinic
trial
howev
exist
compound
tri
exampl
balapiravir
known
hcv
polymeras
inhibitor
test
clinic
found
inact
dengueinduc
cytokin
product
inhibit
convers
prodrug
activ
form
adenosin
analog
shown
activ
dengu
yellow
fever
west
nile
virus
cell
cultur
assay
anim
model
abandon
due
toxic
concern
also
activ
zika
viru
cell
cultur
assay
mous
model
natur
safeti
concern
paramount
greatest
medic
need
treat
pregnant
women
anoth
import
area
pointofcar
diagnost
essenti
distinguish
infect
dengu
chikungunya
chik
zika
virus
great
progress
made
see
next
section
develop
mous
model
describ
justin
juland
utah
state
univers
logan
ut
usa
viru
replic
occur
wildtyp
wt
mice
typic
infect
caus
diseas
contrast
mice
lack
alpha
beta
gamma
ifn
receptor
prove
good
choic
model
zika
viru
infect
follow
subcutan
sc
inocul
mice
zika
viru
variou
paramet
evalu
diseas
sign
includ
conjunct
hunch
lethargi
excit
hindlimb
paralysi
bodi
weight
measur
viremia
test
potenti
antivir
compound
mice
infect
zika
malaysia
viru
sc
pfu
observ
least
week
viremia
peak
day
reduc
baselin
day
compound
administ
twice
daili
bid
day
start
h
infect
studi
paramet
weight
chang
surviv
viremia
sever
known
compound
test
includ
activ
compound
far
viral
rna
polymeras
inhibitor
previous
shown
activ
cell
cultur
assay
wide
rang
rna
virus
includ
filovirus
ebola
marburg
flavivirus
eg
yellow
fever
test
two
dose
mgkg
higher
dose
gave
good
protect
surviv
wherea
lower
dose
delay
death
surviv
day
treat
group
littl
chang
weight
baselin
wherea
placebo
group
lost
weight
experi
also
uninfect
untreat
mice
gain
weight
throughout
period
contrast
mice
treat
mgkg
remain
baselin
weight
doserespons
reduct
viremia
surviv
mice
treat
higher
dose
rechalleng
diseas
mortal
observ
test
therapeut
studi
treatment
start
day
postinfect
dpi
good
protect
surviv
group
treat
day
delay
start
treatment
reduct
efficaci
although
mean
day
death
delay
mice
treat
begin
dpi
although
yellow
fever
vaccin
use
attenu
strain
viru
highli
efficaci
mani
year
sinc
novel
dna
yfvax
technolog
may
offer
import
advantag
need
cold
chain
distribut
high
genet
stabil
reduc
product
cost
use
needlefre
administr
eg
patch
need
adjuv
technolog
adapt
viral
vaccin
johan
neyt
rega
institut
univers
leuven
belgium
report
preclin
research
dnayfvax
hamster
dnayfvax
induc
high
level
antibodi
good
cellular
immun
respons
compar
standard
yellow
fever
vaccin
justin
juland
show
dnayfvax
standard
vaccin
gave
protect
hamster
model
yellow
fever
plan
use
technolog
creat
dnazika
vaccin
johan
report
receiv
zika
viru
transcript
requir
progress
work
minisymposium
organis
mark
prichard
univers
alabama
birmingham
birmingham
al
usa
session
introduc
mark
mani
year
seem
littl
progress
made
design
diagnost
kit
specif
virus
antivir
compound
treat
virus
market
diagnost
assay
e
assay
way
develop
specif
antivir
recent
technolog
develop
assay
platform
perform
multiplex
pcr
reaction
broken
neg
cycl
much
recent
progress
made
use
one
platform
diagnost
laboratori
month
fig
mark
comment
idea
mani
case
adenoviru
infect
pediatr
popul
hospit
thought
good
time
set
diagnost
minisymposium
recruit
firm
describ
assay
platform
compani
repres
invit
describ
assay
platform
introduc
roch
coba
virolog
assay
pedro
present
gave
account
diagnost
assay
machineri
also
scienc
techniqu
use
within
diagnost
platform
scientif
approach
uniqu
firm
common
theme
manufactur
devis
instrument
small
size
moder
easili
portabl
easi
set
simpl
oper
sampl
prepar
vari
simpl
none
requir
step
autom
result
often
h
present
easilyunderstood
format
progress
ongo
new
system
develop
approv
sever
firm
offer
panel
includ
viral
nonvir
agent
select
caus
particular
set
clinic
symptom
aim
make
easi
physician
choos
correct
test
first
time
avoid
sever
test
sequenc
mani
assay
panel
approv
usa
fda
food
drug
administr
give
idea
rang
attribut
avail
make
person
select
manufactur
attribut
may
avail
one
manufactur
roch
diagnost
corpor
roch
coba
system
use
mani
clinic
trial
antivir
treat
hiv
hbv
hcv
infect
assay
low
detect
limit
wide
linear
rang
import
factor
measur
potenti
high
viral
load
untreat
patient
infect
genmark
diagnost
genmark
system
total
assay
time
h
includ
respiratori
viru
panel
claim
sensit
avail
replac
genmark
machin
come
later
requir
sampl
prepar
fluid
move
electr
assay
time
h
output
simpl
report
infecti
agent
panel
either
detectednot
detect
focu
diagnost
simplexa
seri
develop
sinc
machin
footprint
small
sq
ft
easili
portabl
kg
univers
disc
version
use
untreat
clinic
sampl
swab
csf
stool
urin
blood
cultur
medium
disc
heat
c
break
open
virus
bacteria
spin
separ
debri
viral
rna
result
viral
rna
detect
avail
within
min
luminex
corpor
machin
launch
new
machin
simplifi
assay
requir
sever
panel
develop
exampl
respiratori
pathogen
panel
target
includ
dozen
virus
nonvir
pathogen
gastrointestin
pathogen
panel
target
adenoviru
noroviru
rotaviru
variou
nonvir
pathogen
panel
develop
includ
febril
diseas
agent
bacteri
viral
vectorborn
infect
transmit
mosquito
tick
flea
expand
mosquito
panel
includ
chikungunya
yellow
fever
zika
virus
also
test
malaria
biofir
diagnost
filmarray
machin
small
footprint
h
w
easi
locat
near
patient
assay
requir
min
onhand
time
h
result
fdaapprov
panel
three
includ
virus
togeth
nonvir
pathogen
respiratori
gastrointestin
meningitisenceph
lower
respiratori
panel
develop
thermo
fisher
scientif
cellom
way
differ
markedli
other
minisymposium
system
complex
use
versatil
highli
suitabl
research
assay
develop
cellom
system
claim
abl
cell
base
assay
introduct
mark
summaris
recent
progress
result
implic
fig
first
icar
includ
minisymposium
diagnost
technolog
welltim
innov
minisymposium
organis
graciela
andrei
rega
institut
medic
research
leuven
belgium
rhonda
cardin
cincinnati
children
hospit
medic
center
cincinnati
oh
usa
thoma
lion
children
cancer
research
institut
ccri
vienna
austria
speci
human
adenoviru
hadv
design
g
distribut
among
speci
serotyp
identifi
addit
newli
identifi
type
result
homolog
recombin
event
either
intraspeci
interspeci
cohort
n
pediatr
transplant
patient
die
hadv
infect
contribut
virus
transplantrel
mortal
studi
exceed
speci
hadv
occur
peripher
blood
predomin
speci
c
b
onset
viremia
may
herald
lifethreaten
diseas
nevertheless
screen
method
must
cover
entir
hadv
spectrum
order
detect
rare
occur
speci
exemplifi
patient
display
concomit
presenc
hadv
speci
e
f
b
peripher
blood
moreov
hadv
type
speci
caus
viremia
may
switch
posttranspl
cours
chang
predict
monitor
serial
stool
specimen
highli
effect
antivir
cidofovir
primari
agent
nephrotox
oral
lipidconjug
prodrug
brincidofovir
bcv
appear
better
safeti
profil
data
immunocompromis
patient
limit
patient
hematopoiet
stem
cell
transplant
hsct
incid
hadv
viremia
reportedli
rang
adult
children
accord
current
ecil
european
confer
infect
leukemia
recommend
preemptiv
therapi
start
first
detect
hadv
blood
howev
present
experi
favor
outcom
depend
earli
onset
therapi
current
data
suggest
treatment
decis
base
monitor
stool
specimen
prevent
invas
infect
sourc
hadv
complic
posttranspl
may
de
novo
infect
much
commonli
reactiv
viru
persist
gastrointestin
gi
tract
hadv
replic
epitheli
cell
gitract
conveni
measur
use
stool
sampl
risk
viremia
neglig
presenc
hadv
load
copiesg
increas
critic
threshold
level
p
accord
studi
pediatr
hcst
set
perform
present
institut
presenc
hadv
viremia
invari
preced
detect
viru
stool
p
experi
median
time
span
hadv
detect
fig
develop
rapid
diagnost
panel
initi
selfprogress
circl
stool
exceed
copiesg
first
appear
viru
blood
day
therefor
center
explor
possibl
chang
basi
start
therapi
new
indic
hadv
load
stool
copiesg
although
chang
protocol
expect
benefici
longer
term
better
treatment
option
need
brincidofovir
may
promis
option
develop
addit
antihadv
agent
would
warrant
anoth
emerg
approach
great
potenti
treatment
adopt
tcell
transfer
use
preclin
model
papillomavirusinduc
diseas
defin
novel
therapeut
prevent
strategi
paul
f
lambert
univers
wisconsin
madison
wi
usa
sever
human
virus
well
known
caus
cancer
one
human
papilloma
virus
hpv
especi
role
oncogen
studi
mice
also
possibl
studi
effect
host
factor
particular
potenti
estrogen
act
cofactor
without
insert
estrogen
pellet
cancer
detect
discov
estrogen
contribut
progress
cervic
cancer
furthermor
estrogen
pellet
remov
cancer
regress
although
role
estrogen
human
cervic
cancer
remain
demonstr
known
risk
factor
hpv
oral
contracept
hpv
mani
pregnanc
hpv
hormon
replac
therapi
hrt
point
toward
estrogen
factor
murin
papilloma
viru
report
viru
use
provid
use
model
infect
immunodefici
mice
either
tcell
band
tcell
defici
result
wart
ear
infect
site
although
normal
mice
wart
detect
possibl
uvb
radiat
may
impact
uvb
radiat
given
either
h
h
infect
immunocompet
mice
becom
suscept
virusinduc
wart
give
uvb
radiat
without
shield
head
ear
shown
uvb
act
system
known
uvb
induc
system
immunosuppress
seem
correl
onset
diseas
diseas
follow
least
month
good
opportun
studi
effect
potenti
antipapilloma
viru
compound
timothi
kowalik
univers
massachusett
medic
school
worcest
usa
human
cytomegaloviru
cmv
one
largest
complex
human
virus
viral
dna
base
pair
bp
gene
although
infect
larg
asymptomat
healthi
individu
reinfect
appear
common
contrast
seriou
diseas
seen
immunocompromis
patient
new
born
children
infect
pregnanc
congenit
cmv
ccmv
focu
present
ccmv
individu
may
sever
genotyp
chime
studi
pregnanc
congenit
infect
infant
ccmv
genotyp
report
present
sampl
patient
obtain
variou
site
includ
urin
plasma
saliva
deep
sequenc
cmv
base
sequenc
singl
nucleotid
polymorph
snp
detect
polymorph
site
divers
markedli
herp
virus
epsteinbarr
viru
ebv
also
rna
viru
west
nile
viru
wnv
rna
virus
dengu
viru
denv
hepat
c
viru
hcv
slightli
much
greater
divers
respect
may
expect
divers
randomli
distribut
low
divers
loci
enrich
region
encod
dna
process
enzym
capsid
protein
howev
preval
preexist
drug
resist
allel
around
panel
drug
includ
current
approv
three
develop
viral
dna
polymeras
gene
ul
resist
allel
ganciclovir
gcv
foscarnet
fo
cidofovir
cdv
similar
gene
encod
viral
kinas
phosphoryl
activ
gcv
inhibit
maribavir
mbv
viral
terminas
inhibit
letermovir
target
epitop
pul
monoclon
antibodi
untreat
patient
frequenc
variou
snp
remain
larg
stabl
exampl
one
untreat
ccmv
patient
sever
snp
frequenc
almost
hand
snp
almost
less
day
period
chang
seen
contrast
treat
patient
larg
number
snp
chang
frequenc
high
low
vice
versa
chang
start
immedi
mani
snp
alreadi
switch
frequenc
day
therapi
mani
chang
take
place
next
day
therapi
rapid
cmv
evolut
presum
due
preferenti
select
alreadi
present
variant
rather
creation
new
variant
perhap
surprisingli
ccmv
popul
urin
plasma
sampl
differ
much
unrel
host
summari
cmv
divers
rna
virus
cmv
popul
frequenc
chang
rapidli
colon
new
compart
respons
antivir
therapi
henc
variat
within
host
may
repres
secret
viru
lastli
reinfect
superinfect
immun
individu
common
could
explain
individu
acquir
vast
number
snp
philip
e
pellett
wayn
state
univers
detroit
mi
usa
present
cover
topic
roseoloviru
biolog
spectrum
associ
diseas
use
antivir
like
hcmv
roseolovirus
betaherpesvirus
although
includ
present
summari
focu
assay
differenti
wide
use
recent
find
report
may
also
appli
infect
lymphocyt
use
differ
receptor
respect
virus
wide
distribut
worldwid
seropreval
age
respect
virus
transmit
via
saliva
modul
immun
system
persist
life
wide
dispers
latent
reservoir
reactiv
period
b
genom
contain
telomer
repeat
taaccc
n
involv
recombin
integr
complet
viral
genom
telomer
human
chromosom
integr
hypothes
mechan
latenc
importantli
germ
line
integr
genom
enabl
mendelian
inherit
viru
inherit
chromosom
integr
follow
germ
line
transmiss
essenti
everi
cell
throughout
bodi
contain
least
one
viru
genom
preval
usa
uk
japan
vertic
transmiss
via
confus
horizont
transmiss
occur
popul
whole
blood
individu
viral
load
copiesml
genom
detect
cell
harbor
quiescent
integr
viru
genom
thu
far
associ
angina
pectori
larg
populationbas
studi
bacteri
infect
solid
organ
transplant
recipi
importantli
high
viral
load
individu
lead
misdiagnos
inappropri
therapeut
approach
individu
ill
relat
viru
known
clinic
spectrum
divers
major
caus
roseola
associ
febril
rash
young
children
may
caus
febril
convuls
caus
seriou
neurolog
complic
transplant
recipi
contrast
immunocompet
individu
caus
febril
rash
perhap
roseola
case
rare
may
neurolog
diseas
immunocompromis
patient
exampl
solid
organ
transplant
sot
hematopoiet
stem
cell
transplant
hsct
reactiv
common
caus
littl
diseas
good
diagnost
assay
discrimin
develop
establish
drug
employ
herpesviru
infect
fo
gcv
cdv
limit
activ
longterm
use
immunocompromis
patient
restrict
due
toxic
philip
pellett
mention
present
next
day
jennif
brook
new
drug
filociclovir
nucleosid
analog
fig
good
activ
cmv
b
ec
mm
respect
compound
low
solubl
may
account
oral
absorpt
less
dose
proport
e
exposur
follow
mg
dose
similar
mg
dose
howev
safeti
issu
identifi
small
phase
dose
escal
studi
dose
mg
adopt
tcell
immunotherapi
evalu
infect
transplant
recipi
excel
clinic
respons
rate
n
obtain
approach
viral
peptid
use
stimul
gener
virusspecif
cell
virus
ebv
adv
bkv
cmv
hsct
donor
process
take
day
current
therapi
limit
treat
patient
method
establish
bank
cell
develop
summari
roseolovirus
wide
distribut
common
usual
mild
pathogen
immunocompet
individu
obscur
substanti
contribut
consequenti
diseas
clear
play
pathogen
role
seriou
sometim
fatal
case
febril
statu
epilepticu
mesial
tempor
lobe
epilepsi
immunocompet
individu
well
cn
complic
follow
hematopoiet
stem
cell
transplant
therapeut
approach
avail
evalu
control
clinic
trial
success
multicent
trial
high
prioriti
diseas
target
enabl
studi
less
wellestablish
associ
roseolovirus
ship
iceberg
certainli
virus
wide
distribut
throughout
world
immunocompet
individu
infect
often
go
unnot
critic
still
mani
unknown
applic
new
diagnost
assay
help
defin
diseas
associ
aid
clinic
trial
appear
transit
state
mani
activ
virus
hidden
view
one
consequenti
clinic
effect
becom
ever
visibl
updat
herp
simplex
viru
vaccin
get
closer
david
bernstein
univers
cincinnati
cincinnati
oh
usa
clinic
studi
gsk
vaccin
adjuv
conduct
vaccin
given
seroneg
subject
whose
partner
seroposit
protect
vaccin
men
effect
women
similar
studi
includ
subject
hsv
serostatu
vaccin
gave
addit
protect
seroposit
initi
followup
phase
iii
trial
nih
gsk
women
dual
seroneg
unexpectedli
protect
diseas
diseas
also
vaccin
group
significantli
day
recurr
viral
shed
control
group
recent
genocea
evalu
novel
therapeut
vaccin
gen
contain
tcell
antigen
bcell
antigen
adjuv
efficaci
guinea
pig
model
although
recurr
shed
reduc
prevent
trial
patient
moder
sever
infect
outbreaksyear
evalu
vaccin
administ
three
time
day
interv
viru
shed
monitor
period
baselin
third
vaccin
dose
month
one
year
although
clear
dose
respons
mg
dose
vaccin
halv
day
viru
shed
lesion
period
vaccin
month
month
paramet
similar
placebo
anoth
approach
use
replicationdefici
virus
delet
specif
viral
gene
one
vaccin
gave
good
efficaci
guinea
pig
model
compar
protect
vaccin
search
realli
effect
hsv
vaccin
continu
e
hard
nut
crack
rome
icar
chri
meier
univers
hamburg
describ
synthesi
triphosph
prodrug
tripppro
biolog
activ
nucleosid
analog
initi
use
diphosph
prodrug
report
nonsymmetr
prodrug
deliv
nucleosid
diphosph
select
compar
symmetr
prodrug
result
symmetr
c
h
trippproddbcnatp
shown
report
nonsymmetr
version
bcnatp
synthesis
evalu
meet
two
student
gave
present
section
simon
weis
univers
hamburg
hamburg
germani
simon
describ
synthesi
prodrug
carbovir
cbv
abacavir
abc
symmetr
c
h
trippprocbv
c
h
trippproabc
antihiv
activ
test
cem
cell
lymphoblastoid
tcell
line
compar
cbv
cbv
prodrug
activ
respect
similarli
abc
prodrug
activ
respect
cytotox
prodrug
increas
ratio
respect
result
confirm
prodrug
approach
work
success
even
abc
approv
drug
hiv
therapi
abc
initi
monophosphoryl
act
prodrug
carbovir
monophosph
phosphoryl
triphosph
form
inhibit
hiv
revers
transcriptas
open
door
deliv
triphosph
nucleosid
analog
natur
phosphoryl
vivo
cell
uptak
dipproand
tripppronucleotid
employ
fluoresc
nucleosid
analog
inga
reimer
univers
hamburg
hamburg
germani
inga
describ
synthes
symmetr
c
h
dippro
nonsymmetr
c
h
c
h
dippro
c
h
c
h
tripppro
prodrug
ddbcna
fig
prodrug
incub
cem
cell
either
min
cell
separ
centrifug
lyse
natur
fluoresc
ddbcna
use
detect
level
ddbcna
phosphat
prodrug
desir
dior
triphosph
major
product
incub
min
unexpectedli
incub
nonsymmetr
c
h
c
h
trippproddbcna
min
monophosph
also
present
major
product
min
use
ddbcna
gave
conveni
way
monitor
cellular
entri
prodrug
vari
mask
group
prodrug
optimis
cellular
uptak
specif
convers
triphosph
microwaveassist
synthesi
nucleotid
phosphoramid
cecilia
cima
cardiff
univers
cardiff
wale
uk
mention
potenti
activ
nucleosid
convert
use
antivir
drug
use
protid
approach
first
develop
chri
mcguigan
cardiff
notabl
exampl
sofosbuvir
hcv
tenofovir
alafenamid
hiv
howev
standard
synthesi
use
labil
reagent
room
temperatur
long
time
ca
h
led
poor
yield
highli
modifi
nucleosid
aim
work
develop
improv
synthet
method
use
microwav
irradi
mwi
first
step
select
suitabl
stabl
phosphoramid
reagent
would
retain
reactiv
toward
primari
hydroxyl
group
mwi
condit
initi
evalu
use
mwi
temperatur
c
adenosin
model
compound
fig
yield
desir
product
similar
convent
mwi
heat
respect
reaction
time
much
reduc
h
min
respect
optim
ongo
randal
lanier
chimerix
apex
nc
usa
adenovirus
major
speci
ag
pose
seriou
risk
sever
diseas
transplant
patient
particularli
allogen
hematopoiet
cell
transplant
allo
hct
recipi
although
brincidofovir
bcv
oral
prodrug
cidofocir
cdv
evid
kidney
bone
marrow
toxic
detect
subject
receiv
bcv
two
clinic
trial
evalu
bcv
treat
adv
infect
halt
advis
also
ongo
expand
access
studi
advis
studi
larg
reduct
viral
load
especi
patient
whose
baselin
viral
load
c
ml
fig
adv
resist
mutant
bcv
select
cell
cultur
howev
chang
sensit
bcv
modest
respect
clinic
trial
adv
polymeras
gene
sequenc
case
detect
plasma
adv
end
therapi
one
patient
halt
trial
develop
mutat
therapi
associ
virolog
failur
two
patient
advis
trial
mutat
baselin
complet
virolog
respons
end
therapi
good
result
challeng
cohort
patient
year
isar
present
three
major
award
year
doug
richman
elion
award
bob
vinc
award
jerom
deval
prusoff
award
doug
bob
made
import
contribut
hiv
field
path
toward
discoveri
hiv
therapi
combin
good
safeti
abil
prevent
emerg
hiv
resist
amaz
success
stori
even
start
new
chapter
cabotegravir
efda
potenti
use
therapi
also
prevent
transmiss
atripla
show
way
two
compani
work
togeth
creat
new
simpl
effect
singletablet
regimen
likewis
efda
cabotegravir
combin
one
longact
inject
eg
everi
three
month
would
potenti
limit
hiv
transmiss
even
poorer
countri
world
two
compound
complementari
activ
first
reduc
hiv
dna
product
inhibit
incorpor
host
dna
know
prevent
transmiss
achiev
aim
trial
subject
took
truvada
ftctdf
daili
prior
exposur
prep
transmiss
essenti
prevent
seroconvers
subject
take
drug
daili
howev
trial
also
prove
daili
dose
accept
regimen
trial
particip
women
inject
efdacabotegravir
monthli
contracept
inject
prevent
hiv
transmiss
may
becom
practic
realiti
wherea
sever
excel
hiv
therapi
jerom
deval
point
smallmolecul
drug
approv
negativestrand
rna
virus
none
viru
replic
inhibitor
particular
rsv
infect
young
children
seriou
even
fatal
effect
therapi
jerom
colleagu
set
discov
nucleosid
analog
select
inhibit
rsv
polymeras
chose
aim
nucleosid
analog
potenti
activ
broad
rang
viru
strain
high
genet
barrier
resist
inde
nucleosid
analog
becom
backbon
therapi
herpesvirus
hbv
hcv
hiv
infect
jerom
describ
work
lead
discoveri
al
oral
prodrug
proofofconcept
trial
human
subject
infect
rsv
show
highli
effect
well
toler
current
ongo
clinic
trial
infant
month
old
hospit
rsv
infect
clinicaltrialsgov
identifi
primari
outcom
measur
cover
safeti
issu
secondari
aim
cover
effect
rsv
infect
includ
viral
rna
concentr
nasal
aspir
emerg
resist
chang
rsv
polymeras
also
pharmacokinet
paramet
measur
estim
date
complet
septemb
although
efficaci
adult
trial
excel
hard
predict
effect
infant
littl
natur
immun
rsv
howev
one
hope
al
potenti
becom
gamechang
patient
rsv
infect
two
excel
keynot
lectur
richard
scheuermann
heinz
feldmann
richard
describ
larg
databas
viral
genom
sequenc
enabl
team
find
answer
question
previous
resist
investig
exampl
influenza
epitop
evolv
select
pandem
genet
chang
genom
enteroviru
link
increas
diseas
sever
notabl
neurolog
symptom
heinz
gave
interest
overview
ebola
viru
outbreak
end
optimist
note
tool
help
control
futur
outbreak
rvsvebov
better
instrument
detect
sequenc
sampl
ebola
patient
learnt
need
improv
commun
awar
hope
shall
never
long
outbreak
recent
epidem
year
three
import
report
ebola
trial
publish
favipiravir
guinea
jiki
trial
sissoko
et
al
sierra
leon
bai
et
al
zmapp
prevail
ii
write
group
although
none
trial
prove
activ
treatment
reduc
mortal
variou
trend
mortal
viral
load
symptom
point
toward
benefit
suffici
warrant
evalu
two
favipiravir
trial
use
histor
control
e
report
justifi
decis
pragmat
respons
seriou
concern
rais
local
health
care
team
zmapp
trial
randomis
trial
although
blind
state
report
wonder
number
avail
cours
zmapp
limit
would
enough
avail
zmapp
treat
expect
patient
thu
make
randomis
trial
accept
howev
zmapp
trial
patient
recruit
guinea
standard
care
includ
favipiravir
follow
decis
ministri
health
sure
point
way
possibl
clinic
trial
design
futur
ebola
outbreak
arm
trial
potenti
activ
treatment
exampl
favipiravir
zmapp
highli
activ
treatment
would
soon
becom
appar
vaccin
healthcar
staff
reduc
risk
associ
take
blood
sampl
viral
load
assay
import
paramet
antivir
trial
four
minisymposia
structur
biolog
diagnost
technolog
dna
virus
zika
viru
person
highlight
includ
present
divers
hcmv
e
far
greater
herpesvirus
exampl
one
individu
singl
nucleotid
polymorph
snp
almost
less
typic
preval
preexist
drug
resist
allel
around
panel
drug
includ
current
approv
three
develop
antivir
treatment
rapid
cmv
evolut
presum
due
preferenti
select
alreadi
present
variant
rather
creation
new
variant
also
like
present
open
door
new
opportun
exampl
diagnost
assay
fast
approach
ideal
aim
compact
instrument
simpl
use
type
sampl
sampl
prepar
result
within
hour
initi
selfprogress
circl
open
opportun
develop
drug
virus
similarli
chose
includ
report
prodrug
nucleosid
triphosph
widen
structur
rang
triphosph
analog
may
specif
inhibitor
viral
polymeras
phosphoramid
prodrug
approach
success
exampl
sofosbuvir
tenofovir
alafenamid
standard
synthet
method
led
poor
yield
highli
modifi
nucleosid
e
use
microwav
heat
may
potenti
improv
synthesi
report
end
brincidofovir
good
efficaci
adenoviru
hardtotreat
immunocompromis
patient
three
awarde
gave
excel
lectur
set
standard
rest
meet
togeth
la
jolla
sunshin
memor
icar
e
warmli
thank
isar
organis
deliv
anoth
outstand
meet
